A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.
Penn Researchers Create Novel mRNA-based Avian Flu Vaccine
Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Achieves FDA Clearance for Phase I Trial of its CAR T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iECURE Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
New Method Created for Improving the Resolution of Routine Medical Images
This novel method improves resolution of routine low resolution clinical images, saves MR scan time, and reduces radiation dosage levels for CT scanning.
Moderna Receives FDA Approval for RSV Vaccine Based on Penn Technology
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia.
Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.
Capstan raises $175M Series B
Proceeds from the financing will be used to advance Capstan's lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, CPTX2309, to early clinical proof-of-concept in autoimmune disorders.